We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Aspirin Found to Decrease Stomach Cancer Risk

By LabMedica International staff writers
Posted on 03 Mar 2009
Aspirin users could be 36% less likely to get a type of stomach cancer, according to recent research.

In a study of over 300,000 people, the researchers found that people who had taken aspirin at least once in the previous year were considerably less likely to get noncardia gastric cancer (cancer of the middle or lower parts of the stomach). More...
There was also a 32% reduction for the same type of stomach cancer in individuals who used other types of nonsteroidal antiinflammatory drugs (NSAIDs).

In contrast to results of previous studies, the researchers found that aspirin does not protect against esophageal cancer and cardia gastric cancer, which is cancer of the top of the stomach. Taking aspirin regularly has been found to cut the risk of bowel cancer, but it is not currently recommended because side effects could include bleeding within the abdomen.

Now, scientists believe that placebo-controlled trials, which would evaluate risks and benefits, should be conducted to see if NSAIDs could be used to protect against stomach and esophageal cancers. Five-year survival rates for these cancers are 15 and 8% in the United Kingdom, respectively, so research in how to prevent the disease is important.

Study author Dr. Christian Abnet, based at the U.S. National Cancer Institute (NCI; Rockville, MD, USA), said, "We found that the risk of non-cardia stomach cancer was lower in people who had taken aspirin, and this risk lowered the more regularly they took it. Interestingly, our results didn't show a significant cut in the risk of esophageal or cardia stomach cancer, so it's important that we continue to review data that suggest otherwise. The number of people who survive at least five years following a diagnosis of stomach or esophageal cancer is low, so it's important to increase our understanding of ways to prevent the disease and to investigate aspirin as a possible preventative drug.”

The rate of non-cardia stomach cancer calculated in this study was 7 per 100,000 person-years for aspirin users, compared with 11 per 100,000 person-years for non-users. The figures were calculated from a study of more than 311,000 people in the United States and an analysis of 17 published studies on the topic.

Each year in the United Kingdom, approximately 8,000 people are diagnosed with stomach cancer, and about 5,250 people die from the disease. Dr. Lesley Walker, director of cancer information at Cancer Research UK (London), commented, "It's far too early to recommend that people take aspirin to protect themselves from these cancers. In cancers where survival is low, understanding how to prevent the disease is crucial, but more research is needed to discover how side effects can be balanced with the benefits. Cancer Research UK would urge people to speak to their doctor before taking aspirin regularly.”

The study was published in the February 2009 issue of the British Journal of Cancer (BJC).

Related Links:

National Cancer Institute




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.